News On AgeX Therapeutics Inc. (AGE) Now Under SER
News On AgeX Therapeutics Inc. (AGE) Now Under SER
Serina Therapeutics Announces Completion of Merger With AgeX Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol "SER" on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024;
AgeX Therapeutics GAAP EPS of -$13.73
AgeX Therapeutics Secures Funding, Details in SEC Report
AgeX Therapeutics Postpones Merger Completion With Serina
AgeX Therapeutics Expands Ties With JuvVentures Equity Deal
AgeX Therapeutics Secures $500K Convertible Note Deal
What's Going On With Penny Stock AgeX Therapeutics?
Serina Therapeutics Inc, a privately held, clinical-stage biotechnology company, entered into a License Agreement under which Pfizer Inc (NYSE:PFE) will license, on a non-exclusive basis, Serina's POZ polymer technology.
AgeX Therapeutics Continues To Slide
Serina Therapeutics Announces POZ Polymer Technology License Agreement With Pfizer
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held,
AgeX Therapeutics Q3 EPS $(0.14) Down From $(0.06) YoY, Sales $67.00K Up From $9.00K YoY
AgeX Therapeutics (AMEX:AGE) reported quarterly losses of $(0.14) per share. This is a 133.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $6
AgeX Therapeutics Restructures Debt, Faces Financial Uncertainty
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000
04:19 PM EST, 11/14/2023 (MT Newswires) -- Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000
Press Release: AgeX Therapeutics Reports Third Quarter 2023 Financial Results
AgeX Therapeutics Reports Third Quarter 2023 Financial Results ALAMEDA, Calif.--(BUSINESS WIRE)--November 14, 2023-- AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company dev
AgeX Therapeutics 3Q Rev $67,000 >AGE
AgeX Therapeutics 3Q Rev $67,000 >AGE
Shareholder Alert: Ademi LLP Investigates Whether AgeX Therapeutics, Inc. Has Obtained a Fair Price in Its Transaction With Serina
MILWAUKEE, Aug. 30, 2023 /PRNewswire/ -- Ademi LLP is investigating AgeX (NYSE American: AGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Serina. Click
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating AgeX Therapeutics, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - August 30, 2023) - Rigrodsky Law, P.A. is investigating AgeX Therapeutics, Inc. ("AgeX") (NYSE American: AGE) regarding possible breaches of fiduciary duties an
AgeX Therapeutics Shares Rise Premarket on Reverse Merger Deal >AGE
By Colin Kellaher Shares of AgeX Therapeutics moved higher in premarket trading Wednesday after the biotechnology company said it agreed to an all-stock reverse merger with clinical-stage biotechnolo
AgeX Therapeutics: Serina Holders to Own About 75% of Combined Company >AGE
AgeX Therapeutics: Serina Holders to Own About 75% of Combined Company >AGE
Serina Therapeutics and AgeX Therapeutics Enter Into Merger Agreement
Serina Therapeutics and AgeX Therapeutics Enter Into Merger Agreement
No Data